LNT | 7578-24-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: LNT
• 英文别名: lacto-N-tetraose；Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta；N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
• CAS: 7578-24-7
• 化学式: C₂₆H₄₅NO₂₁
• 分子量: 707.637
• InChiKey: AXQLFFDZXPOFPO-UNTPKZLMSA-N

物化性质

• 沸点：
  1116.1±65.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -7.9
• 重原子数：
  48
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  357
• 氢给体数：
  14
• 氢受体数：
  21

反应信息

• 作为反应物：
  描述：

  LNT 在 碳酸氢铵 作用下， 以 二甲基亚砜 为溶剂， 反应 72.0h， 以74%的产率得到N-((2S,3R,4R,5S,6R)-2-(((2S,3R,4S,5S,6R)-2-(((2R,3S,4R,5R)-6- amino-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)- oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)- oxy)-5-hydroxy-6-(hydroxymethyl)-4-(((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro2H-pyran-3-yl)acetamide
  参考文献：
  名称：

  Bioorthogonal human milk oligosaccharide probes for antimicrobial target identification within Streptococcus agalactiae

  摘要：

  Human milk oligosaccharides (HMOs) are a structurally diverse class of carbohydrates that possess strong antibacterial activity against Streptococcus agalactiae (Group B Strep, GBS). This work highlights the design, synthesis, and retained biological activity of several HMO bioorthogonal probes within GBS, a first in class advance. The use of such probes will assist in identifying HMO-protein interactions within GBS and may be broadly applicable in researching HMO cellular targets within a variety of biological systems. Finally, this strategy is highly amenable to other oligosaccharide scaffolds, requiring minimal synthetic transformations and chemical perturbation.

  DOI：

  10.1016/j.carres.2019.107895
• 作为产物：
  描述：

  benzyl O-β-D-galactopyranosyl-(1->3)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1->3)-O-β-D-galactopyranosyl-(1->4)-O-β-D-glucopyranoside 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 水 为溶剂， 50.0 ℃ 、400.01 kPa 条件下， 反应 1.5h， 以78%的产率得到LNT
  参考文献：
  名称：

  [EN] SYNTHESIS OF HMO CORE STRUCTURES
  [FR] SYNTHÈSE DE STRUCTURES À NOYAU HMO

  摘要：

  该发明涉及一种制备HMO核心结构前体的方法，包括以下步骤：将N-乙酰乳糖胺或乳酸-N-双糖衍生物供体与乳糖或N-乙酰乳糖胺衍生物受体反应，其中供体是一种噁唑烷供体。

  公开号：

  WO2013044928A1

文献信息

• [EN] A METHOD FOR OBTAINING CRYSTALLINE LACTO-N-TETRAOSE AND LACTO-N-NEOTETRAOSE PRECURSORS AND MIXTURES THEREOF<br/>[FR] PROCÉDÉ POUR OBTENIR DES PRÉCURSEURS DE LACTO-N-TÉTRAOSE ET DE LACTO-N-NEOTÉTRAOSE CRISTALLIN ET DES MÉLANGES DE CEUX-CI
  申请人：GLYCOM AS

  公开号：WO2013091660A1

  公开（公告）日：2013-06-27

  A mixture of, preferably a mixture consisting essentially of, an lacto-N-tetraose (LNT) precursor (1) and an lacto-N-neotetraose (LNnT) precursor (2), (formula 1, 2), where R is a group removable by hydrogenolysis and R3 is either a group removable by hydrogenolysis or H, a method of crystallizing 1 and/or 2 from said mixture, and the use of said mixture for making a mixture consisting essentially of LNnT and LNT for use as a pharmaceutically or nutritionally active ingredient. The precursors can be made by reacting an acceptor of formula 5, (formula 5), wherein R is a group removable by hydrogenolysis, R1 is acyl, Ri is acyl or H, R3 is selected from a group removable by hydrogenolysis, acyl, silyl and an acetal type group and Y is selected from alkanoylamido, haloalkanoylamido, -NAc2, benzamido, alkoxycarbonylamino, haloalkoxycarbonylamino, benzyloxycarbonylamino, azido, phthalimido, tetrachlorophthalimido, 2,3- diphenylmaleimido and 2,3-dimethylmaleimido, with a donor of formula 6, (formula 6), wherein R4 is acyl and Xi is selected from halogen, -OC(=NH)CCl3, -OAc, -OBz or -SR5, wherein R5 is selected from alkyl, substituted phenyl and unsubstituted phenyl, followed by one or more deprotection steps.

  一种混合物，优选基本上由乳糖-N-四糖（LNT）前体（1）和乳糖-N-新四糖（LNnT）前体（2）（式1，2）组成，其中R是通过氢解可移除的基团，R3是可通过氢解移除的基团或H，从该混合物中结晶1和/或2的方法，以及该混合物用于制备基本上由LNnT和LNT组成的混合物，作为药用或营养活性成分的用途。这些前体可以通过反应一个受体式5（式5），其中R是通过氢解可移除的基团，R1是酰基，Ri是酰基或H，R3是从可通过氢解移除的基团、酰基、硅基和缩醛型基团中选择的，Y是从烷酰胺基、卤代烷酰胺基、-NAc2、苯甲酰胺基、烷氧羰基氨基、卤代烷氧羰基氨基、苄氧羰基氨基、叠氮基、邻苯二甲酰亚胺基、四氯邻苯二甲酰亚胺基、2,3-二苯基马来酰亚胺基和2,3-二甲基马来酰亚胺基中选择的，与一个供体式6（式6）反应，其中R4是酰基，Xi是从卤素、-OC(=NH)CCl3、-OAc、-OBz或-SR5中选择的，其中R5是从烷基、取代的苯基和未取代的苯基中选择的，随后进行一个或多个脱保护步骤来制备。
• Synthesis of lacto- N -tetraose
  作者：Kelly M. Craft、Steven D. Townsend

  DOI：10.1016/j.carres.2017.02.001

  日期：2017.2

  Human milk oligosaccharides (HMOs) are the third largest macromolecular component of breast milk and offer infants numerous health benefits, most of which stem from the development of a healthy microbiome. Characterization, quantification, and chemical derivatization of HMOs remains a frontier issue in glycobiology due to the challenge of isolating appreciable quantities of homogenous HMOs from breast milk. Herein, we report the synthesis of the human milk tetrasaccharide lacto-N-tetraose (LNT). LNT is ubiquitous in human breast milk as it is a core structure common to longer-chain HMOs and many glycolipids. (C) 2017 Elsevier Ltd. All rights reserved.
• [EN] DERIVATIZATION OF OLIGOSACCHARIDES<br/>[FR] DÉRIVATION D'OLIGOSACCHARIDES
  申请人：GLYCOM AS

  公开号：WO2012007585A9

  公开（公告）日：2012-07-26
• [EN] SYNTHESIS OF HMO CORE STRUCTURES<br/>[FR] SYNTHÈSE DE STRUCTURES À NOYAU HMO
  申请人：GLYCOM AS

  公开号：WO2013044928A1

  公开（公告）日：2013-04-04

  The invention relates to a method for making precursors of HMO core structures comprising a step of reacting an N-acetyllactosamine or lacto-N-biose derivative donor with a lactose or N-acetyllactosamine derivative acceptor, wherein the donor is an oxazoline donor.

  该发明涉及一种制备HMO核心结构前体的方法，包括以下步骤：将N-乙酰乳糖胺或乳酸-N-双糖衍生物供体与乳糖或N-乙酰乳糖胺衍生物受体反应，其中供体是一种噁唑烷供体。
• Bioorthogonal human milk oligosaccharide probes for antimicrobial target identification within Streptococcus agalactiae
  作者：Schuyler A. Chambers、Steven D. Townsend

  DOI：10.1016/j.carres.2019.107895

  日期：2020.2

  Human milk oligosaccharides (HMOs) are a structurally diverse class of carbohydrates that possess strong antibacterial activity against Streptococcus agalactiae (Group B Strep, GBS). This work highlights the design, synthesis, and retained biological activity of several HMO bioorthogonal probes within GBS, a first in class advance. The use of such probes will assist in identifying HMO-protein interactions within GBS and may be broadly applicable in researching HMO cellular targets within a variety of biological systems. Finally, this strategy is highly amenable to other oligosaccharide scaffolds, requiring minimal synthetic transformations and chemical perturbation.